Overall survival outcomes for breast cancer brain metastasis patients.

FDA approval of PATHWAY HER2 (4B5) test expands diagnostic capabilities ... Roche’s PATHWAY (4B5), when used with the BenchMark IHC/ISH slide staining system, standardizes immunohistochemistry ...

Treatment for HER2-positive breast cancer depends on tumor size and spread but may involve a combination of chemotherapy, targeted therapy, monoclonal antibody therapy, and kinase inhibitors.

Thus, interference with host protein glycosylation by viral proteins competing for the modification process may cause ER stress. Rotavirus studies propose that the double-layered particle ...

(“The Pitt” is a double entendre, referring to both Pittsburgh Medical Trauma Hospital’s namesake city and its employees’ nickname for the ER.) Wyle’s “ER” character began as a fresh ...

Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from AstraZeneca/Daiichi Sankyo and Roche.

Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death.

These are pretreated and laundered industrial stain monitors that Andrea used during detergent testing. The bottom-middle monitor shows stains pretreated and washed with Tide Free & Gentle.

The approval allows certain patients to receive Enhertu earlier in their treatment course. Credit: FatCamera via Getty Images. AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu ...

Get Instant Summarized Text (Gist) Trastuzumab emtansine (T-DM1) significantly improves long-term survival in high-risk HER2-positive breast cancer patients post-surgery, reducing the risk of ...

Future Oncol. 2015;11(7):1023-1026. Tumor-negative breast cancers misclassified as HER2 negative by IHC (0 or 1+) could therefore be reclassified by FISH, with a remarkable impact on medical ...